VNDA Soars, CEMI Secures Zika Contract, EMA To Review MYL's Proposed Biosimilar

Shares of Vanda Pharmaceuticals Inc. (VNDA) soared more than 20% on Thursday, following a favorable verdict in the patent litigation against Roxane Laboratories Inc. related to schizophrenia drug Fanapt.

from RTT - Biotech http://ift.tt/2cd9xUf
via IFTTT